Free Trial
NASDAQ:XOMA

XOMA Royalty Q2 2025 Earnings Report

XOMA Royalty logo
$36.68 +0.97 (+2.72%)
Closing price 09/26/2025 04:00 PM Eastern
Extended Trading
$36.85 +0.17 (+0.48%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

XOMA Royalty EPS Results

Actual EPS
$0.48
Consensus EPS
-$0.12
Beat/Miss
Beat by +$0.60
One Year Ago EPS
N/A

XOMA Royalty Revenue Results

Actual Revenue
$13.13 million
Expected Revenue
$9.39 million
Beat/Miss
Beat by +$3.74 million
YoY Revenue Growth
N/A

XOMA Royalty Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Wednesday, August 13, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

XOMA Royalty's Q3 2025 earnings is scheduled for Thursday, November 6, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

XOMA Royalty Earnings Headlines

Arizona-made nanochips the new millionaire maker?
George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the last 40 years. Now he's stepping forward with an even bigger prediction about what's being built in the Arizona desert. He believes 3 little-known companies will explode when a bombshell announcement just days from now. Smart investors are already positioning themselves.tc pixel
ESSA Pharma Inc. Amends Agreement with XenoTherapeutics
See More XOMA Royalty Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like XOMA Royalty? Sign up for Earnings360's daily newsletter to receive timely earnings updates on XOMA Royalty and other key companies, straight to your email.

About XOMA Royalty

XOMA Royalty (NASDAQ:XOMA) (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases. XOMA Royalty partners with biopharmaceutical companies across North America, Europe and other key markets, supporting the continued development and commercialization of innovative treatments. Its due-diligence process emphasizes assets with compelling clinical data, robust intellectual property protection and clear regulatory pathways.

Led by a management team with extensive experience in pharmaceutical finance, licensing and royalty management, XOMA Royalty leverages industry relationships to source and structure transactions. The board comprises executives and advisors with backgrounds in drug development, investment banking and asset management, positioning the company to identify high-quality royalty opportunities and steward its growing portfolio over time.

View XOMA Royalty Profile

More Earnings Resources from MarketBeat